Noah 1993

Methods	Randomized controlled trial Duration: 13 months, from November 1987 to December 1988
Participants	Number: 96 infants enrolled: 69 with lymphadenitis; 27 with abscess formation Inclusion criteria: infants with lymphadenitis or abscess with a diameter of at least 2 cm within 6 months of BCG vaccination Exclusion criteria: not stated
Interventions	Group A (lymphadenitis group): received either 1) erythromycin PO (50 mg/kg/day for one month) or 2) oral placebo. Group B (abscessed group): all had their abscess aspirated, then randomized to 1) erythromycin PO (50 mg/kg/day for one month) plus a single local instillation of saline (placebo), or 2) oral placebo plus locally instilled isoniazid (50 mg single dose)
Outcomes	Clinical failure (abscess formation/lymph node size increased)
Notes	Location: Jamaica Setting: emergency department community based‐trial Source of funding: not described
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described in the study
Allocation concealment (selection bias)	Unclear risk	Not described in the study
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Use of placebo (coloured sugar water).
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Although subjective, the authors clearly define 'clinical resolution'
Incomplete outcome data (attrition bias) All outcomes	Low risk	No patients were lost to follow‐up
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement
Other bias	Unclear risk	There was insufficient information to assess whether an important risk of bias exists